Reference health
The Inflammatory Chemokine CCL5 and Cancer Progression
1 of 93 checkable references need attention · checked 2026-07-23
At the dated check, the references listed below either did not resolve in Crossref or DataCite, or carried a retraction notice. Each one is shown with the registry record that put it there.
10 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
References needing attention
marked retracted — notice via Crossref, record curated by Retraction Watch10.1002/ijc.20784
<i>Retracted</i>
: Transactivation of the
<i>CCL5/RANTES</i>
gene by Epstein‐Barr virus latent membrane protein 1
The 92 checked references that resolve
resolves10.1016/j.ccr.2012.02.022
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
resolves10.1200/JCO.2012.46.3653
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
resolves10.1002/path.2711
The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape
resolves10.1182/blood-2011-10-386763
PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma
resolves10.1158/0008-5472.CAN-11-2493
Tumor-Derived Chemokine CCL5 Enhances TGF-β–Mediated Killing of CD8+ T Cells in Colon Cancer by T-Regulatory Cells
resolves10.1186/2045-3701-3-5
One cell, multiple roles: contribution of mesenchymal stem cells to tumor development in tumor microenvironment
resolves10.4049/jimmunol.1201018
Tumor-Infiltrating Monocytic Myeloid-Derived Suppressor Cells Mediate CCR5-Dependent Recruitment of Regulatory T Cells Favoring Tumor Growth
resolves10.1007/s12307-011-0094-3
The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNFα and Chemokines
resolves10.1038/nature06188
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
resolves10.1016/j.cellsig.2004.04.007
Chemokine receptor CCR5: insights into structure, function, and regulation
resolves10.3109/10428194.2011.605190
The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment
resolves10.4049/jimmunol.1101883
IL-15 Can Signal via IL-15Rα, JNK, and NF-κB To Drive RANTES Production by Myeloid Cells
resolves10.1111/bjh.12226
Potent <i>in vitro</i> and <i>in vivo</i> activity of sorafenib in multiple myeloma: induction of cell death, <scp>CD</scp>138‐downregulation and inhibition of migration through actin depolymerization
resolves10.1182/blood-2003-02-0488
RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement
resolves10.1016/j.bcp.2008.11.014
CCL5 increases lung cancer migration via PI3K, Akt and NF-κB pathways
resolves10.1002/stem.1194
Autocrine CCL5 Signaling Promotes Invasion and Migration of CD133
<sup>+</sup>
Ovarian Cancer Stem‐Like Cells via NF‐κB‐Mediated MMP‐9 Upregulation
resolves10.1016/j.cyto.2013.06.313
CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling
resolves10.3858/emm.2008.40.5.514
LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression
resolves10.1371/journal.pone.0035101
CCL5 and CCR5 Interaction Promotes Cell Motility in Human Osteosarcoma
resolves10.1182/blood-2003-11-3839
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion
resolves10.1016/j.exphem.2004.11.015
MIP-1α utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells
resolves10.1007/s10585-006-9038-6
Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model
resolves10.1111/j.1365-2141.2004.04864.x
Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)‐1<i>α</i> and MIP‐1<i>β</i> correlates with lytic bone lesions in patients with multiple myeloma
resolves10.1046/j.1365-2141.2003.04561.x
Serum levels of macrophage inflammatory protein‐1 alpha (MIP‐1α) correlate with the extent of bone disease and survival in patients with multiple myeloma
resolves10.1038/leu.2009.130
Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma
resolves10.1038/leu.2011.43
A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
resolves10.1016/j.exphem.2010.06.012
The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients
resolves10.1182/blood.V100.6.2195
Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma
resolves10.1182/blood-2002-08-2383
Macrophage inflammatory protein 1-alpha (MIP-1α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells
resolves10.1038/sj.leu.2402717
Expression and function of chemokine receptors in human multiple myeloma
resolves10.1182/blood-2011-10-384784
CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease
resolves10.1093/annonc/13.S1.52
Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues
resolves10.1002/ijc.11370
Expression of CCL5/RANTES by Hodgkin and Reed‐Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue
resolves10.1002/ijc.23119
Expression of CCR5 receptors on Reed–Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions
resolves10.1111/j.1365-2141.2007.06964.x
Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22
resolves10.1016/S0002-9440(10)63187-2
Expression of CCL28 by Reed-Sternberg Cells Defines a Major Subtype of Classical Hodgkin's Disease with Frequent Infiltration of Eosinophils and/or Plasma Cells
resolves10.2353/ajpath.2008.070845
Expression of the Epstein-Barr Virus-Encoded Epstein-Barr Virus Nuclear Antigen 1 in Hodgkin's Lymphoma Cells Mediates Up-Regulation of CCL20 and the Migration of Regulatory T Cells
resolves10.1182/blood.V94.6.2065
Hodgkin/Reed-Sternberg Cells Induce Fibroblasts to Secrete Eotaxin, a Potent Chemoattractant for T Cells and Eosinophils
resolves10.1111/j.1365-2141.2010.08497.x
IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion
resolves10.1182/blood-2009-10-247809
Chemokine receptors as therapeutic tools in Hodgkin lymphoma: CCR4 and beyond
resolves10.1093/carcin/bgr009
Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis
resolves10.3892/or_00000331
Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24− phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression
resolves10.1038/cmi.2012.69
CCL5 as a potential immunotherapeutic target in triple-negative breast cancer
resolves10.1111/j.1349-7006.2012.02259.x
Chemokine <scp>C</scp>‐<scp>C</scp> motif receptor 5 and <scp>C</scp>‐<scp>C</scp> motif ligand 5 promote cancer cell migration under hypoxia
resolves10.4161/cam.25138
Mesenchymal stem cell-derived CCL-9 and CCL-5 promote mammary tumor cell invasion and the activation of matrix metalloproteinases
resolves10.1038/cr.2012.178
A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells
resolves10.1158/1078-0432.CCR-06-0074
The Chemokine CCL5 as a Potential Prognostic Factor Predicting Disease Progression in Stage II Breast Cancer Patients
resolves10.1155/2013/453561
Circulating CCL5 Levels in Patients with Breast Cancer: Is There a Correlation with Lymph Node Metastasis?
resolves10.1158/1541-7786.MCR-12-0217
STAT3-RANTES Autocrine Signaling Is Essential for Tamoxifen Resistance in Human Breast Cancer Cells
resolves10.1046/j.1523-1747.2002.01725.x
The Role of Chemokines in Melanoma Tumor Growth and Metastasis
resolves10.1038/sj.bjc.6690164
The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice
resolves10.1002/ijc.2910560617
Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes
resolves10.1016/j.humpath.2006.11.013
Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma
resolves10.1371/journal.pone.0033747
Deficiency of C-C Chemokine Receptor 5 Suppresses Tumor Development via Inactivation of NF-κB and Upregulation of IL-1Ra in Melanoma Model
resolves10.1016/S0960-9822(01)00199-3
A potential immune escape mechanism by melanoma cells through the activation of chemokine-induced T cell death
resolves10.1016/j.jss.2005.04.030
Metastases-Related Genes in the Classification of Liver and Peritoneal Metastasis in Human Gastric Cancer
resolves10.1016/S0959-8049(02)00596-8
Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor
resolves10.5483/BMBRep.2003.36.1.082
Chemoprevention of Helicobacter pylori-associated Gastric Carcinogenesis in a Mouse Model; Is It Possible?
resolves10.1002/jso.20984
Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer
resolves10.1002/ijc.23401
Gastric cancer cells exploit CD4+ cell‐derived CCL5 for their growth and prevention of CD8+ cell‐involved tumor elimination
resolves10.1371/journal.pone.0028842
CCL5 Neutralization Restricts Cancer Growth and Potentiates the Targeting of PDGFRβ in Colorectal Carcinoma
resolves10.1371/journal.pone.0004608
The Prostate Specific Membrane Antigen Regulates the Expression of IL-6 and CCL5 in Prostate Tumour Cells by Activating the MAPK Pathways1
resolves10.1016/j.ygyno.2006.01.029
Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder
resolves10.1038/onc.2008.274
MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death
resolves10.1158/2159-8290.CD-12-0206
MicroRNAs Reprogram Normal Fibroblasts into Cancer-Associated Fibroblasts in Ovarian Cancer
resolves10.1073/pnas.96.10.5698
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
resolves10.1016/j.ejmech.2012.07.049
Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents
resolves10.1016/j.bmcl.2010.06.003
Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents
resolves10.1016/j.bmcl.2012.05.127
The potential role of anibamine, a natural product CCR5 antagonist, and its analogues as leads toward development of anti-ovarian cancer agents
resolves10.1093/annonc/mdr159
Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer
resolves10.1002/jcb.24456
Gefitinib inhibits the cross‐talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity
resolves10.1038/nri2972
Overcoming hurdles in developing successful drugs targeting chemokine receptors
The 10 references without a DOI — listed, not checked
no DOI — not checked31
no DOI — not checked57
no DOI — not checked58
no DOI — not checked66
no DOI — not checked69
no DOI — not checked79
no DOI — not checked89
no DOI — not checked91
no DOI — not checked96
no DOI — not checked97
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1155/2014/292376"><img src="https://citestamp.com/citestamped/10.1155/2014/292376/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1155/2014/292376)